Notably, SMYD1 expression was significantly decreased only in the TP53 mutation group of STAD patients, whereas SMYD4 was significantly increased only in the TP53 mutation group of ESCA patients. The gene discussed is SMYD1; the disease is gastric adenocarcinoma.